These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17641999)

  • 1. ALLICENSE 2007--A Recombinant Capital Conference. Enhancing productivity through alliances.
    Pestonjamasp V
    IDrugs; 2007 Jun; 10(6):377-82. PubMed ID: 17641999
    [No Abstract]   [Full Text] [Related]  

  • 2. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 4. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 6. Today's biotech industry in India.
    Suresh N
    Biotechnol J; 2009 Mar; 4(3):291-4. PubMed ID: 19296434
    [No Abstract]   [Full Text] [Related]  

  • 7. Fresh horizons South Korea.
    Cyranoski D
    Nature; 2002 Dec; 420(6916):4-5. PubMed ID: 12478244
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 9. Stepping up to the plate.
    Nat Immunol; 2008 Jan; 9(1):1. PubMed ID: 18087245
    [No Abstract]   [Full Text] [Related]  

  • 10. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toronto rising.
    Kleiner K
    Nature; 2008 May; 453(7192):252-3. PubMed ID: 18561361
    [No Abstract]   [Full Text] [Related]  

  • 13. San Diego.
    Howard K
    Nature; 2003 Dec; 426(6967):689. PubMed ID: 14668871
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 15. Rediscovering plant-based drugs.
    Littleton J; Falcone D; Davies HM
    Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmas partner in venture seeking drug discovery tools.
    Mack GS
    Nat Biotechnol; 2008 Sep; 26(9):960-1. PubMed ID: 18779790
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotechnology consortia versus multifirm alliances: paradigm shift at work?
    Persidis A; Persidis A
    Nat Biotechnol; 1996 Dec; 14(13):1657-60. PubMed ID: 9634847
    [No Abstract]   [Full Text] [Related]  

  • 18. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 20. Wrong numbers?
    Nat Biotechnol; 2010 Aug; 28(8):761. PubMed ID: 20697382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.